Hutchison MediPharma (“HMP”) is an innovative biopharmaceutical company based in China and the Innovation Platform of its parent company, Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM). Established in 2002, HMP is focused on the discovery and development of small-molecule compounds against novel but relatively well-characterized targets with global first-in-class potential against these targets, as well as compounds against validated targets to potentially be global best-in-class, next-generation therapies with a superior profile compared to existing approved drugs that act against these targets.
We have assembled a leading drug research and development team in China to create a large-scale and fully-integrated drug discovery and development operation covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls, clinical and regulatory and other functions, which work seamlessly together.
Our approach has been to create a stable and supportive environment that allows our research and development team to innovate. We believe we have succeeded in this, and as of December 31, 2017, we and our collaboration partners have invested about $500 million in the discovery and development activities of HMP. This has resulted in a significant clinical pipeline consisting of eight small molecule tyrosine kinase inhibitors, which are currently being investigated in clinical studies in 36 target patient populations around the world.
Our success in research and development has led to partnerships with leading global pharmaceutical companies, including AstraZeneca, Eli Lilly and Nestlé Health Science.